These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 7687163)

  • 1. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
    Rostaing-Capaillon O; Casellas P
    Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
    Rasmussen RA; Counts SL; Lambert JM; Collinson AR
    Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.
    Porro G; Bolognesi A; Caretto P; Gromo G; Lento P; Mistza G; Sciumbata T; Stirpe F; Modena D
    Cancer Immunol Immunother; 1993 May; 36(5):346-50. PubMed ID: 7682894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
    Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.
    Gasanov SE; Rael ED; Gasanov NE; Vernon LP
    Cancer Immunol Immunother; 1995 Aug; 41(2):122-8. PubMed ID: 7544687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.
    Zhu Z; Kralovec J; Ghose T; Mammen M
    Cancer Immunol Immunother; 1995 Apr; 40(4):257-67. PubMed ID: 7750124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for the Analysis of the Tumor Microenvironment by Mass Cytometry: Application to Chronic Lymphocytic Leukemia.
    Gonder S; Fernandez Botana I; Wierz M; Pagano G; Gargiulo E; Cosma A; Moussay E; Paggetti J; Largeot A
    Front Immunol; 2020; 11():578176. PubMed ID: 33193376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli.
    Mazzarello AN; Fitch M; Cardillo M; Ng A; Bhuiya S; Sharma E; Bagnara D; Kolitz JE; Barrientos JC; Allen SL; Rai KR; Rhodes J; Hellerstein MK; Chiorazzi N
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations.
    Nixon AML; Duque A; Yelle N; McLaughlin M; Davoudi S; Pedley NM; Haynes J; Brown KR; Pan J; Hart T; Gilbert PM; Singh SK; O'Brien CA; Sidhu SS; Moffat J
    Sci Rep; 2019 Jan; 9(1):842. PubMed ID: 30696911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.
    Fuchs H; Weng A; Gilabert-Oriol R
    Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.
    Gilabert-Oriol R; Weng A; Mallinckrodt Bv; Melzig MF; Fuchs H; Thakur M
    Curr Pharm Des; 2014; 20(42):6584-643. PubMed ID: 25341935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization.
    Faguet GB; Agee JF
    Blood; 1993 Jul; 82(2):536-43. PubMed ID: 7687163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.